In Brief: Medical Developments International, Ventracor, Anadis, Ozgen, GlaxoSmithKline
Thursday, 14 July, 2005
Chris Weaver has resigned as Medical Developments Internationa (ASX:MVP) managing director and CEO to take up an executive management position with a bank. Current CFO Jeremy Payling will act as interim CEO while the company searches for a new CEO. Payling has also been appointed to the newly created position of chief operating officer. Former AusBiotech head Tony Coulepis has been appointed as a director.
Jane Wilder, former company secretary and corporate solicitor for Tempo Services, will replace Bernadette Kerrigan as Ventracor's (ASX:VCR) company secretary and legal counsel.
Anadi (ASX:ANX) has appointed part-time consultant to the company, Arie Nudel, as a director.
Perth-based GM mouse supplier Ozgene has entered into a license agreement with French company Cellectis to use its patent for creating, developing and selling mice relating to mouse knock-ins.
GlaxoSmithKline's anti-thrombotic drug Arixtra has been approved by the European Commission for use in surgical patients at high risk of life-threatening venous blood clots. This follows US FDA approval of the same indication in May. Arixtra is a synthetic form of the natural anti-clotting agent heparin, and Brisbane biopharma Alchemia (ASX:ACL) has an identical, generic molecule ready for launch when GSK's five-year market exclusivity expires next year.
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
